Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGiC: Lapatinib + CapeOx in HER2+ Advanced Gastric/Esophageal Cancer
NCT00680901Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of lapatinib in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Novartis. Started Jun 2008; status: completed.
02
Drugs
lapatinib
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00680901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00680901.